Literature DB >> 32440912

Practical Procedures for Improving Detection of Circulating miRNAs in Cardiovascular Diseases.

Chia-Chun Chen1,2, Chen-Ching Peng3, Pei-Chun Fan4,5, Pao-Hsien Chu6, Yu-Sun Chang3,7, Chih-Hsiang Chang4,5.   

Abstract

Hemolysis has been known to affect the measurement of circulating biomarkers. In this study, clinically applicable procedures for microRNA (miRNA) detection in serum samples of acute myocardial infarction patients were established. The 89 samples from patients admitted to the coronary care unit were collected. These samples obtained from heparin-treated and untreated patients were subjected to heparinase digestion prior to miRNA measurements by multiplex RT-qPCR. The good reproducibility of miRNA detection after heparinase digestion (average R2 = 0.97) indicated that this method can be used routinely for samples regardless of heparin medication. Additionally, the degree of hemolysis in these samples was highly related to the hemoglobin absorbance at 414 nm. Based on the hemoglobin absorbance, five hemolysis-associated miRNAs were identified in our data normalized with respect to both the spike-in control and the RNA amount in a given sample. Using these calibration procedures, miRNAs can be accurately quantified and identified for clinical samples. Graphical Abstract The practical procedures for miRNA detection in serum samples from the coronary care unit were established, and five hemolysis-associated miRNAs were accurately clarified through serial normalization.

Entities:  

Keywords:  Hemolysis; Heparin; Heparinase; MicroRNA; Normalization

Mesh:

Substances:

Year:  2020        PMID: 32440912     DOI: 10.1007/s12265-020-10019-2

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  17 in total

1.  Assessing sample and miRNA profile quality in serum and plasma or other biofluids.

Authors:  Thorarinn Blondal; Søren Jensby Nielsen; Adam Baker; Ditte Andreasen; Peter Mouritzen; Maria Wrang Teilum; Ina K Dahlsveen
Journal:  Methods       Date:  2012-10-02       Impact factor: 3.608

2.  [Polyploid hybrids of Saccharomyces cerevisiae, differing in their enzyme activity during molasses fermentation].

Authors:  K V Kosikov
Journal:  Mikrobiologiia       Date:  1977 Mar-Apr

3.  Differences in the morphogenetic properties of mouse and chick embryonic liver cells.

Authors:  M L Burdick
Journal:  J Exp Zool       Date:  1972-04

4.  [Contribution to morphology of human spleen. 3. Arterial and venous "vessel section" in parenchyma].

Authors:  F Kikkawa
Journal:  Okajimas Folia Anat Jpn       Date:  1969-03

5.  [Electrophysiologic study of the influence of the cerebellar dentate nucleus on brain activity in epilepsy].

Authors:  V Drlicková; P Nádvorník
Journal:  Cesk Neurol Neurochir       Date:  1987-05

6.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR).

Authors:  Evan M Kroh; Rachael K Parkin; Patrick S Mitchell; Muneesh Tewari
Journal:  Methods       Date:  2010-02-08       Impact factor: 3.608

Review 7.  MicroRNA profiling: approaches and considerations.

Authors:  Colin C Pritchard; Heather H Cheng; Muneesh Tewari
Journal:  Nat Rev Genet       Date:  2012-04-18       Impact factor: 53.242

8.  The Impact of Hemolysis on Cell-Free microRNA Biomarkers.

Authors:  Michaela B Kirschner; J James B Edelman; Steven C-H Kao; Michael P Vallely; Nico van Zandwijk; Glen Reid
Journal:  Front Genet       Date:  2013-05-24       Impact factor: 4.599

9.  Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs.

Authors:  Jaynish S Shah; Patsy S Soon; Deborah J Marsh
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

10.  Optimized Collection Protocol for Plasma MicroRNA Measurement in Patients with Cardiovascular Disease.

Authors:  Chi-Sheng Wu; Fen-Chiung Lin; Shu-Jen Chen; Yung-Lung Chen; Wen-Jung Chung; Cheng-I Cheng
Journal:  Biomed Res Int       Date:  2016-09-20       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.